Lopez JS, Harrington KJ, Im SA, Lee KW, et al. Phase 1 study of ceralasertib, an ATR kinase inhibitor, in combination with durvalumab in patients with recurrent or metastatic NSCLC or HNSCC. Br J Cancer 2026;134:1568-1579.
PMID: 41917211